Astemizole: An old anti-histamine as a new promising anti-cancer drug

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 307-314

  García Quiroz, Janice ^a   Camacho, Javier ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Anticancer drugs; Astemizole; Eag1; Erg; Histamine; Potassium channels; QT interval

Indexed keywords

ARPROMIDINE; ASTEMIZOLE; CIMETIDINE; CLOBENPROPIT; DIMAPRIT; FAMOTIDINE; HISTAMINE; IMETIT; POTASSIUM CHANNEL HERG; PROTEIN EAG 1; RANITIDINE; TERFENADINE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CANCER DIAGNOSIS; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; QT INTERVAL; REVIEW; TORSADE DES POINTES; TUMOR CELL;

EID: 79954480293     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795347513     Document Type: Review

References (81)

1. Parsons, M.E.; Ganellin, C.R. Histamine and its receptors. Br. J. Pharmacol., 2006, 147(suppl. 1), S127-S135.
2. Cricco, G.P.; Davio, C.A.; Martín, G.; Engel, N.; Fitzsimons, C.P.; Bergoc, R.M.; Rivera, E.S. Histamine as an autocrine growth factor in experimental mammary carcinomas. Agents actions, 1994, 43(1-2), 17-20.
3. Bowrey, P.F.; King, J.; Magarey, C.; Shwartz, P.; Marr, P.; Bolton, E.; Morris, D.L. Histamine, mast cells and tumor cell proliferation in breast cancer: does preoperative cimetidine administration have an effect?. Br. J. Cancer, 2000, 82, 167-170.
4. Lampiasi, N.; Azzolina, A.; Montalto, G.; Cervello, M. Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp. Mol. Med., 2007, 39, 284-294.
5. Cricco, G.; Martin, G.; Labombarda, F.; Cocca, C.; Bergoc, R.; Rivera, E. Human pancreatic carcinoma cell line Panc-I and the role of histamine on cell growth. Inflamm. Res., 2000, 49(suppl1), S68-S69.
6. Cricco, G.P.; Mohamad, N.A.; Sambuco, L.A.; Genre, F.; Croci, M.; Gutiérrez, A.S.; Medina, V.A.; Bergoc, R.M.; Rivera, E.S.; Martín, G.A. Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors. Inflamm. Res., 2008, 57(suppl 1), S23-S24.
7. Adams, W.J.; Lawson, J.A.; Morris, D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut, 1994, 35, 1632-1636.
8. + immature myeloid cells. Nature Medicine, 2011, 7(1), 87-95.
9. Norrby, K. Evidence of mast-cell histamine being mitogenic in intact tissue. Agents actions, 1985, 16, 287-290.
10. Reynolds, J.L.; Akhter, J.; Morris, D.L. in vitro effect of histamine and histamine H1 and H2 receptor antagonist on cellular proliferation of human malignant melanoma cell lines. Melanoma Res.,1996, 6, 95-99.
11. Genre, F.; Valli, E.; Medina, V.; Gutiérrez, A.; Sambuco, L.; Rivera, E.; Cricco, G.; Martín, G. Effect of histamine on the expression of metalloproteinases and cell adhesion in breast cancer cell lines. Inflamm. Res., 2009, 58(supll 1) S55-S56.
12. Blaya, B.; Nicolaou-Galmes, F.; Jangi, S.M.; Ortega-Martinez, I.; Alonso-Tejerina, E.; Burgos-Bretones, J.; Perez-Yarza, G.; Asumendi, A.; Boyano, M.D. Histamine and histamine receptor antagonists in cancer biology. Infl. & Allergy-Drug Targets, 2010, 9(3), 146-157.
13. Adams, W.J.; Lawson, J.A.; Morris, D.L. The growth of carcinogen induced colon cancer in rats is inhibited by cimetidine. Eur. J. Surg. Oncol., 1993, 19, 332-335.
14. Jiang, C.; Liu, F.; Yu, M., Li, J.; Xu, H. Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo. Oncology Reports, 2010, 23(3), 693-700.
15. Jangi, S.; Díaz-Pérez, J. L.; Ochoa-Lizarralde, B.; Martín-Ruiz, I.; Asumendi, A.; Pérez-Yarza, G.; Gardeazabal, J.; Díaz-Ramón, J. L.; Boyano, M. D. H1 histamine receptor antagonists induces genotoxic and caspase-2-dependent apoptosis in human melanoma cells. Carcinogenesis, 2006, 27(9), 1787-1796.
16. Diccionario de especialidades farmacéuticas, ed. 50; México, 2004. http://www.libreriamedica8a.com/productos/2015.htm (Accesed February 17, 2011).
17. DrugBank. http://www.drugbank.ca/drugs/DB00637 (Accesed February 17, 2011).
18. Simons, F.E.R.; Kesselman, M.S.; Giddins, N.G.; Pelech, A.N.; Simons, K.J. Astemizole-induced torsade de pointes. Lancet, 1988, 2, 624.
19. Davies, A.J.; Harindra, V.; McEwan, A.; Ghose, R.R. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ., 1989, 298(6669), 325.
20. Monahan, B.P.; Ferguson, C.L.; Killeavy, E.S. Torsades de pointes occurring in association with terfenadine use. JAMA, 1990, 264, 2788-2790.
21. Wang, Q.; Shen, J.; Splawski, I.; Atkinson, D.; Li, Z.; Robinson, J.L.; Moss, A.J.; Towbin, J.A.; Keating, M.T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell, 1995, 80, 805-811.
22. Roy, M.L.; Dumaine, R.; Brown, A.M.; HERG a primary human ventricular target of the nonsedating anti-histamine terfenadine. Circulation, 1996, 94, 817-823.
23. Yang, W.P.; Levesque, P.C.; Little, A.L.; Conder, M.L.; Shalaby, F.Y.; Blanar, M.A. KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc. Nat. Acad. Sci., 1997, 94, 4017-4021.
24. Lawrence, M.; DuBuske, M.D. Second-generation anti-histamines: the risk of ventricular arrhythmias. Clin. Therap., 1999, 21(2), 281-295.
25. Paakkari, I. Cardiotoxicity of new anti-histamine and cisapride. Toxicol. Lett., 2002, 127, 279-284.
26. Berul, C.I.; Morad, M. Regulation of potassium channels by nonsedating anti-histamines. Circulation, 1995, 91, 2220-2225.
27. Vorperian, V.; Zhou, Z.; Mohammad, S.; Hoon, T.J.; Studenik, C.; January, C.T. Torsade-de pointes with an anti-histamine metabo lite: potassium channel blockade with desmethylastemizole. JACC, 1996, 28, 1556-1561.
28. Bachmann, K.A. Norastemizole Sepracor. Curr. Opin. Investig. Drugs., 2000, 1(2), 219-226.
29. Lee, E.H.; Oh, J.H.; Park, H.J.; Kim, D.G.; Lee, J.H.; Kim, C.Y.; Kwon, M.S.; Yoon, S. Simultaneous gene expression signature of heart and peripheral blood mononuclear cells in astemizole-treated rats. Arch. Toxicol., 2010, 84, 609-618.
30. Kingswood, J.C.; Routledge, P.A.; Lazaris, J.H. A report of overdose with astemizole. Human Toxicol., 1986, 5, 43-44.
31. Bishop, R.O.; Gaudry, P.L. Prolongated Q-T interval following astemizole overdose. Arch. Emerg. Med., 1989, 6, 63-65.
32. Woosley, R.L. Cardiac actions of anti-histamines. Annu. Rev. Pharmacol. Toxicol., 1996, 36, 233-252.
33. Craft, T.M. Torsade de pointes after astemizole overdose. Br. Med. J., 1986, 292, 660.
34. Saviuc, P.; Danel, V.; Dixmerias, F. Prolonged QT interval and torsade de pointes following astemizole overdose. Clin. Toxicol., 1993, 31(1), 121-125.
35. Rao, K.A.; Adlakha, A.; Verma-Ansil, B.; Meloy, T.D.; Salton, M.S. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo. Clin. Proc., 1994, 69, 589-593.
36. Ikeda, S.; Oka, H.; Matunaga, K.; Kubo, S.; Asai, S.; Miyahara, Y.; Osaka, A.; Kohno, S. Astemizole-induced torsades de pointes in a patient with vasospastic angina. Jpn. Circ. J. 1998, 62, 225-227.
37. Snook, J.; Boothman-Burrell, D.; Watkins, J.; Colin-Jones, D.; Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br. J. Clin. Pract. 1988, 42, 257-258.
38. Hoppu, K.; Tikanoja, T.; Tapanainen, P.; Remes, M.; Saarenpää-Heikkilä, O.; Kouvalainen, K. Accidental astemizole overdose in young children. Lancet, 1991, 338, 538-540.
39. Lindquist, M., Edwards, R.I. Risk of non-sedating anti-histamines. Lancet, 1997, 349, 1322.
40. Salata, J.J.; Jurkiewicz, N.K.; Wallace, A.A.; Stupienski, R.F.; Guinosso, P.J.; Linch, J.J. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Res., 1995, 76, 110-119.
41. De Abajo, F.J.; García-Rodríguez L.A. Risk of ventricular arrhythmias associated with nonsedating anthistamine drugs. Br. J. Clin. Pharmacol., 1999, 47, 307-313.
42. Craft, T.M.; Vanden, B.G.; De Cree, J.; Griffiths, J.V. ECG studies with astemizole. Hum. Toxicol., 1987, 6(6), 527-528.
43. Zhou, Z.; Vorperian, V.R.; Gong, Q.; Zhang, S.; January, C.T.; Block of HERG potassium channels by the channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol., 1999, 10, 836-843.
44. Asher, V.; Sowter, H.; Shaw, R.; Bali, A.; Khan, R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J. Surgical Oncology., 2010, 8(113), 1-9.
45. García-Ferreiro, R. E.; Kerschensteiner, D.; Major, F.; Monje, F.; Stühmer, Pardo, L.A. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J. Gen. Physiol., 2004, 124, 301-317.
46. Gómez-Varela, D.; Contreras-Jurado, C.; Furini, S.; García-Ferreiro, R.; Stümher, W.; Pardo, L.A. Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. FEBS Lett., 2006, 580, 5059-5066.
47. Pardo, L.A.; Contreras-Jurado, C.; Zientkowska, M.; Alves, F.; Sthümer, W. Role of voltage-gated potassium channels in cancer. J. Membr. Biol., 2005, 205, 115-124.
48. Kunzelman K. Ion channels and cancer. J. Membr. Biol., 2005, 205, 159-173.
49. Ouadid-Ahidouch, H.; Ahidouch, A. K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J. Membrane Biol., 2008, 221, 1-6.
50. Fraser, S.P.; Pardo, L.A.; Ion channels: functional expression and therapeutic potential in cancer. EMBO Reports, 2008, 9, 512-515.
51. Lang, F.; Föller, M.; Lang, K.S.; Lang, P.A.; Ritter, M.; Gulbins, E.; Vereninov, A.; Huber, S.M. Ion channels in cell proliferation and apoptotic cell death. J. Membrane Biol., 2005, 205, 147-157.
52. Lang, F.; Foller, M.; Lang, K. S.; Lang, P. A.; Ritter, M.; Gulbins, E.; Vereninov, A.; Huber, S. M. Ion channels in cell proliferation and apoptotic cell death. J. Membrane Biol., 2005, 205, 147-157.
53. Brevet, M.; Fucks, D.; Chatelain, D.; Regimbeau, J.M.; Delcenserie, R.; Sevestre, H.; Ouadid-Ahidouch, H. Deregulation of 2 potassium channels in pancreas adenocarcinomas. Pancreas, 2009, 38, 649-654.
54. Pardo, L.A.; Del Camino, D.; Sánchez, A.; Alves, F.; Brüggemann, A.; Beckh, S.; Stühmer, W. Oncogenic potential of EAG K+ channels. EMBO J., 1999, 18(20), 5540-5547.
55. Wadhwa, S.; Wadhwa, P.; Dinda, A.K.; Gupta, N.P. Diferential expression of potassium ion channels in human renal cell carcinoma. Int. Urol. Nephrol., 2009, 41(2), 251-257.
56. Bielanska, J.; Hernández-Losa, J.; Pérez-Verdaguer, M.; Moline, T.; Somoza, R.; Ramóny Cajal, S.; Condom, E.; Ferreres, J.C.; Felipe, A. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Current Cancer Drug Targets, 2009, 904-914.
57. Asher, V.; Sowter, H.; Shaw, R.; Bali, A.; Khan, R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J. Surg. Oncol., 2010, 8, 113.
58. Bianchi, L.; Wible, B.; Arcangeli, A.; Taglialatela, M.; Morra, F.; Castaldo, P.; Crociani, O.; Rosati, B.; Faravelli, L.; Olivotto, M.; Wanke, E. herg encodes a K+ current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells. Cancer Res., 1998, 58, 815-822.
59. Pillozi, S.; Brizzi, M.F.; Balzi, M.; Cherubini, A.; Guasti, L.; Bartolozzi, B.; Bechetti, A.; Wanke, E.; Bernabei, P.A.; Olivotto, M.; Pegoraro, L.; Arcangeli, A. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia, 2002, 16, 1791-1798.
60. Cherubini, A.; Taddei, G.L.; Crociani, O.; Paglierani, M.; Fontana, L.; Noci, I.; Borri, P.; Borrani, E.; Giachi, M.; Bechetti, A.; Rosati, B.; Wanke, E.; Olivotto, M.; Arcangeli, A. HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous andometrium. Br. J. Cancer, 2000, 83(12), 1722-1729.
61. Lastraioli, E.; Guasti, L.; Crociani, O.; Polvani, S.; Hofmann, G.; Witchel, H.; Bencini, L.; Calistri, M.; Messerini, L.; Zcatizzi, M.; Moretti, R.; Wanke, E.; Olivotto, M.; Mugnai, G.; Arcangeli, A. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res., 2004, 64, 606-611.
62. Chen, S.; Jiang, M.; Zhen, Y.; HERG K+ channel expressionrelated chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother. Pharmacol., 2005, 56, 212-220.
63. Zhao, J.; Wei, X.; Jia, Y.; Zheng, J. Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo. Eur. J. Pharmacol., 2008, 579, 50-57.
64. Camacho, J. Ether à go-go potassium channels and cancer. Cancer Lett., 2006, 233, 1-9.
65. Hemmerlein, B.; Weseloh, R.M.; Mello de Queiroz, F.; Knötgen, H.; Sánchez, A.; Rubio, M.E.; Martin, S.; Schliephacke, T.; Jenke, M.; Heinz-Joachim-Radzum; Stühmer, W.; Pardo, L.A. Overexpression of EAG1 potassium channels in clinical tumours. Mol. Cancer, 2006, 5(41), 1-13.
66. Ochiodoro, T.; Bernheim, L.; Liu, J.; Bijlenga, P.; Sinnreich, M.; Bader, C. R.; Fisher-Lougheed, J. Cloning of human ether a-go-go potassium channel expressed in myoblastos at the onset fusion. FEBS lett., 1998, 434, 177-182.
67. Farias, L.M.B.; Ocaña, D.B.; Díaz, L.; Larrea, F.; Avila-Chávez, E.; Cadena, A.; Hinojosa, L.M.; Lara, G.; Villanueva, L.A.; Vargas, C.; Hernández-Gallegos, E.; Camacho-Arroyo, I.; Dueñas-González, A.; Pérez-Cárdenas, E.; Pardo, L.A.; Morales, A.; Taja-Chayeb, L.; Escamilla, J.; Sánchez-Peña, C.; Camacho, J. Ether à go-go potassium channels as human cervical cancer markers, Cancer Res., 2004, 64, 6996-7001.
68. García-Becerra, R.; Diaz, L.; Camacho, J.; Barrera, D.; Ordaz-Rosado, D.; Morales, A.; Ortiz, C.S.; Avila, E.; Bargallo, E.; Arrecillas, M.; Larrea, F. Clcitriol inhibits Ether-à-go-go potassium cannel expression and cell proliferation in human breast cancer cells. Exp. Cell Res., 2010, 316, 433-442.
69. Díaz, L.; Ceja-Ochoa, I.; Restrepo-Angulo, I.; Larrea, F.; Avila-Chávez, E.; García-Becerra, R.; Borja-Cacho, E.; Barrera, D.; Ahumada, E.; Gariglio, P.; Alvarez-Rios, E.; Ocadiz-Delgado, R.; García-Villa, E.; Hernández-Gallegos, E.; Camacho-Arroyo, I.; Morales, A.; Ordaz-Rosado, D.; García-Latorre, E.; Escamilla, J.; Sánchez-Peña, L.M.; Saqui-Salces, M.; Gamboa-Dominguez, A.; Vera, E.; Uribe-Ramírez, M.; Murbartián, J.; Ortiz, C.S.; Rivera-Guevara, C.; Vizcaya-Ruiz, A.; Camacho, J. Estrogens and human papiloma virus oncogenes regulate human Ether-à-go-go-1 potassium channel expression. Cancer Res.; 2009, 69(8), 3300-3307.
70. Meyer, R.; Schonherr, R.; Gavrilova-Ruch, O.; Wohlrab, W.; Heinemann, S.H. Identification of ether à go-go and calcium activated potassium channels in human melanoma cells. J. Membr. Biol. 1999, 171, 107-115.
71. Ding, X.; Luo, H.; Jin, X. Aberrant expression of Eag1 potassium channel in gastric cancer patients and cell lines. Med. Oncol., 2007, 24, 345-350.
72. Downie, B.R.; Sánchez, A.; Knötgen, H.; Contreras-Jurado, C.; Gymnopoulos, M.; Weber, C.; Stühmer, W.; Pardo, L.A. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J. Biol. Chem., 2008, 283(52), 36234-36240.
73. Borowiec, A.S.; Hague, F.; Harir, N.; Guénin, S.; Guerineau, F.; Gouilleux, F.; Roudbaraki, M.; Lassoued, K.; Ouadid-Ahidouch, H. IGF-1 activates hEAG K+ channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J. Cell. Physiol. 2007, 212, 690-701.
74. Gómez-Varela, D.; Zwick-Wallasch, E.; Knötgen, H.; Sánchez, A.; Hettmann, T.; Ossipov, D.; Weseloh, R.; Contreras-Jurado, C.; Rothe, M.; Stühmer, W.; Pardo, L.A. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res., 2007, 67(15), 7343-7349.
75. Pardo, L.A.; Stühmer, W. Eag1: An emerging oncological target. Cancer Res., 2008, 68(6), 1611-1613.
76. Weber, C.; Mello de Queiroz, F.; Downie, B.R.; Suckow, A.; Stühmer, W. Pardo, L.A. Silencing the activity and proliferative properties of the human Eag1 potassium cannel by RNA interference. J. Biol. Chem., 2006, 13030-13037.
77. Gavrilova-Ruch, O.; Schönherr, K.; Gessner, G.; Klapperstück, T.; Wohlrab, W.; Heinemann, S.H. Effects of imipramina on ion channels and proliferation of IGR1 Melanoma Cells. J. Membr. Biol., 2002, 188, 137-149.
78. + channel function in the human mammary carcinoma cell lines MCF-7. Oncol. Reports, 2008, 19, 1511-1516.
79. Ouadid-Ahidouch, H.; Roudbaraki, M.; Delcourt, P.; Ahidouch, A.; Joury, N.; Prevarskaya, N. Functional and molecular identification of intermediate-conductance Ca2+-activated K+ channels in breast cancer cells: association with cell cycle progression. AJP-Cell Physiol., 2004, 287, C125-C134.
80. Davenport, A.J.; Möller, C.; Heifetz, A.; Mazanetz, M.P.; Law, R.J.; Ebneth, A.; Gemkow, M. Using electrophysiology and in silico Three-dimensional modeling to reduce human Ether-à-go-go related gene K+ channel inhibition in a histamine H3 receptor antagonist program. ASSAY and Drug Development Technologies, 2010, 8(6), 781-789.
81. Kamb, A., Wee, S., Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 2007, 6, 115-120.